CC
RYTM icon

Checkpoint Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Checkpoint Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107M Buy
1,227,200
+235,000
+24% +$22.9M 38.3% 2
2025
Q4 		$106M Buy
992,200
+228,493
+30% +$24.2M 33.18% 2
2025
Q3 		$77.1M Sell
763,707
-296,293
-28% -$27.5M 25.84% 2
2025
Q2 		$67M Buy
1,060,000
+152,760
+17% +$9.35M 31.21% 2
2025
Q1 		$48.1M Buy
907,240
+179,258
+25% +$9.95M 26.37% 2
2024
Q4 		$40.8M Buy
727,982
+64,601
+10% +$3.57M 20.74% 2
2024
Q3 		$34.8M Sell
663,381
-258,719
-28% -$12.4M 17.24% 2
2024
Q2 		$37.9M Buy
922,100
+96,600
+12% +$3.86M 22.82% 1
2024
Q1 		$35.8M Buy
825,500
+95,500
+13% +$4.18M 23.91% 1
2023
Q4 		$33.6M Buy
+730,000
New +$23M 20.33% 1

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Checkpoint Capital's RYTM Position: Q1 2026 in Review

Checkpoint Capital increased its Rhythm Pharmaceuticals (RYTM) stake by 24% in Q1 2026, buying an estimated $22.9M and bringing the position to 1,227,200 shares worth $107M. The position accounts for 38.3% of the portfolio, ranked #2.

Checkpoint Capital first reported a position in RYTM in Q4 2023 and has held it in 10 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Checkpoint Capital held 1,227,200 shares of Rhythm Pharmaceuticals worth $107M as of Q1 2026.
  • Checkpoint Capital bought 235,000 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $22.9M.
  • Rhythm Pharmaceuticals made up 38.3% of Checkpoint Capital's portfolio in Q1 2026, its #2 holding.
  • Checkpoint Capital first reported a position in Rhythm Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Checkpoint Capital's 13F filing for Q1 2026, filed 15 May 2026.